diABZI3

diABZI3 (also known as diABZI-3 or diABZI STING agonist-1) is a potent, selective, non-nucleotide small-molecule agonist of the Stimulator of Interferon Genes (STING) pathway. Originally developed by GSK, diABZI3 is a dimeric amidobenzimidazole compound designed to mimic the activity of cyclic dinucleotides (CDNs) like cyclic GMP-AMP (cGAMP) but with improved cellular permeability and stability. By binding to STING, diABZI3 induces the phosphorylation of TBK1 and IRF3, leading to the robust production of type I interferons (such as IFN-beta) and proinflammatory cytokines. It has been investigated preclinically for its immunotherapeutic potential in various cancers (such as colorectal cancer), viral infections (including SARS-CoV-2), and parasitic diseases like schistosomiasis, where it helps modulate host immune responses and reduce immunopathology.

Other names

CS-0029879CS0029879CS 0029879Diamidobenzimidazole STING Agonist 1Diamidobenzimidazole STING Agonist 3Diamidobenzimidazole Stimulator of Interferon Genes Agonist 1Diamidobenzimidazole Stimulator of Interferon Genes Agonist 3EX-A3217EX-A-3217EX-A 3217HY-103665HY103665HY 103665HY-112921HY112921HY 112921HY-112921AHY112921AHY 112921AHY-112921BHY112921BHY 112921BSTING agonist (compound 3)STING agonist-3VBN99291VBN-99291VBN 99291diABZI STING agonist 1diABZI STING agonist 3diABZI STING agonist-1diABZI Stimulator of Interferon Genes Agonist 1diABZI Stimulator of Interferon Genes Agonist 3diABZI compound 3diABZI-3diABZI3diABZI 3